DUBLIN, March 09, 2022–(BUSINESS WIRE)–The report “Insulin Patch Pump Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029” has been added to from ResearchAndMarkets.com offer.

Diabetes is a chronic disease that affects around 415 million people worldwide and is expected to reach 642 million by 2040. People with diabetes need to take insulin for life.

Thus, the development of insulin patch pump technology offers increased benefits over traditional multiple daily injection therapy. Increasing adoption rate of non-invasive techniques in transdermal drug delivery practices would drive the growth of the insulin patch pump market over the forecast period. Additionally, the increasing prevalence of diabetes across the world along with advancements in technology are driving the insulin pump market.

In order to assist strategic decision makers, the report also includes a competitive profile of key players in the global Insulin Pumps market, attractive investment proposition and market positioning of key manufacturers sections.

The market size and forecast for these regional and national markets are presented in this study for the period 2019-2029. Market growth rates for the forecast period 2019-2029 are also included in this report, considering 2020 as the base year.

Thus, the research study provides a holistic view of the global Oral Thin Film Drugs market, offering market size and estimates for the period 2019 to 2029, keeping the above mentioned factors in mind.

According to the type of insulin

Insulin patch pumps are wearable devices attached to the body that deliver insulin at a specific rate at regular intervals. An insulin patch pump aims to deliver insulin painlessly without tubing or an infusion set, making it convenient and safe to use.

Different types of insulin patch pumps have been developed such as bolus insulin pumps to release insulin at a rapid rate to counter the rise in blood sugar levels after meals. While basal insulin pumps are a long-acting insulin therapy to control blood sugar levels between meals and during sleep.

The story continues

The growing prevalence of diabetes at an alarming rate is the major driver for the growth of the insulin pump market. Additionally, rapid technological advancements in glucose monitoring over the past decade have supported the growth of the insulin patch pump market. Additionally, increasing adoption rate of non-invasive techniques in transdermal drug delivery practices would further drive the growth of the insulin patch pump market during the forecast period 2021 to 2029.

According to the type of condition

The increasing prevalence of diabetes is the major driver for the growing demand for the insulin patch pump market. There are two major types of diabetes such as type 1 diabetes and type 2 diabetes. Type 2 diabetes held the largest market share in the insulin pump market owing to the fact that it is is the most common type of diabetes, accounting for 90% to 95% of cases.

Although insulin is not the first line of treatment for treating type 2 diabetes, many patients end up needing insulin for the best possible glycemic control when needed. Insulin patch pumps provide a hassle-free option for insulin delivery that sticks directly to the skin without tubing compared to other medication delivery options such as insulin pumps and pens. The major players operating in the market are targeting type 2 diabetes due to higher target population compared to type 1 diabetes.

For example, in 2021, Becton Dickenson & Co. announced its interest in diving into the emerging patch insulin pump market for patients with type 2 diabetes, with a product launch expected in 2018. patch insulin pumps for type 2 diabetes is expected to flourish during the forecast period.

For the purpose of this study, the global insulin pump patch market is classified as follows:

In the benchmark year 2020, North America held the largest market in the insulin patch pump market. The United States is the top market in the region due to the high adoption of new technologies and non-invasive techniques.

Moreover, the continuous increase in the number of patients suffering from diabetes is fueling the market. According to the US National Diabetes Statistics Report 2021, approximately 30.3 million people of all ages, or 9.4% of the total US population, had diabetes in 2019.

Additionally, approximately 1.5 million new cases of diabetes have been diagnosed in adults ages 18 and older in the United States. Asia-Pacific is expected to witness a boom in the insulin patch pump market as numerous products are expected to hit the market during the forecast period of 2021 to 2029. Additionally, the increase in population target and growing awareness of new technological advancements in insulin pumps would further drive the market.

Main topics covered:

Chapter 1 Preface

1.1 Description of the report

1.2 Scope of research

1.3 Research methodology

Chapter 2 Executive Summary

2.1 Insulin Pump Market Overview

2.2 Insulin pump market, by insulin type, 2020 (Million USD)

2.3 Insulin pump market, by condition type, 2020 (Million USD)

2.4 Insulin Pump Market, by Geography, 2020 (Value %)

Chapter 3 Global Insulin Pump Market Analysis

3.1 Global Insulin Pump Market Overview

3.2 Market Dynamics

3.2.1 Market Drivers

3.2.2 Challenges

3.2.3 Opportunities

3.3 Mergers, acquisitions and business strategies

3.4 Porter’s analysis

3.5 Attractive investment proposition

3.6 Competitive Analysis: Global Insulin Pump Market, 2020 (Value %)

Chapter 4 Global Insulin Pump Market Analysis, By Insulin Type

4.1 Overview

4.1.1 Insulin Patch Pump Market Benchmarking, By Insulin Type, 2020

4.2 Bolus insulin

4.3 Basal insulin

4.4 Basal-bolus insulin

Chapter 5 Global Insulin Pump Market Analysis, By Condition Type

5.1 Presentation

5.1.1 Insulin Pump Market Benchmarking, by Condition Type, 2020

5.2 Type 1 diabetes

5.3 Type 2 diabetes

Chapter 6 Global Insulin Pump Market, By Geography

6.1 Preface

Chapter 7 Company Profiles

• Island Corporation

• Johnson & Johnson

• Medtrum Technologies Inc.

• Roche Holding AG

• Cellnovo Group SA

• Spring Health Solutions Ltd.

• Debiotech

• CeQur SA

• Valeritas

• Becton Dickenson & Company

For more information about this report visit https://www.researchandmarkets.com/r/adl81i

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220309005673/en/

contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Officer
[email protected]
For EST business hours, call 1-917-300-0470
For US/CAN call toll free 1-800-526-8630
For GMT office hours call +353-1-416-8900